Does Mao Inhibitors Interact with Phenobarbital Sodium?
CDI records a moderate classification for Mao Inhibitors and Phenobarbital Sodium. The stored summary is: Inhibitors may increase phenobarbital exposure, increasing risk of adverse reactions. Closely monitor and consider dosage adjustment. The mechanism involves phenobarbital is a substrate of cyp2c9, cyp2c19, cyp2e1, and ugts; inhibition reduces metabolism. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Phenobarbital is a substrate of CYP2C9, CYP2C19, CYP2E1, and UGTs; inhibition reduces metabolism
What To Tell Your Doctor or Pharmacist
If you are taking Mao Inhibitors and your doctor is considering prescribing Phenobarbital Sodium (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider